Akira Ohkoshi

Department Of Otolaryngology Head And Neck Surgery
Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.

Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 03, 2026

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 26, 2026

Oncological and functional outcomes of frontolateral vertical partial laryngectomy in selected patients with cT3N0 glottic carcinoma.

Oncological and functional outcomes of frontolateral vertical partial laryngectomy in selected patients with cT3N0 glottic carcinoma.

Journal: Auris, nasus, larynx

Published: June 15, 2026

A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca17Mab-5, for Multiple Applications.

A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca17Mab-5, for Multiple Applications.

Journal: Antibodies (Basel, Switzerland)

Published: May 21, 2026

Association of Imaging-Defined Deep Invasion and Tumor Volume With Clinical Cervical Lymph Node Metastasis in Hypopharyngeal Carcinoma.

Association of Imaging-Defined Deep Invasion and Tumor Volume With Clinical Cervical Lymph Node Metastasis in Hypopharyngeal Carcinoma.

Journal: Journal of computer assisted tomography

Published: May 01, 2026

Inverse Relation Between Responses to Pembrolizumab Plus Chemotherapy and Subsequent Cetuximab Plus Paclitaxel in Head and Neck Cancer: Role of the Janus Kinase-Signal Transducer and Activator of Transcription Signaling Pathway.

Inverse Relation Between Responses to Pembrolizumab Plus Chemotherapy and Subsequent Cetuximab Plus Paclitaxel in Head and Neck Cancer: Role of the Janus Kinase-Signal Transducer and Activator of Transcription Signaling Pathway.

Journal: JCO precision oncology

Published: April 23, 2026

Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial.

Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial.

Journal: Oral oncology

Published: February 02, 2026

Superselective intra-arterial chemoradiotherapy for maxillary sinus squamous-cell carcinoma: results from the T4bN0M0 cohort of JCOG1212.

Superselective intra-arterial chemoradiotherapy for maxillary sinus squamous-cell carcinoma: results from the T4bN0M0 cohort of JCOG1212.

Journal: ESMO open

Published: January 27, 2026

Treatment and prognosis of subglottic cancers: a 10-year, multicenter, retrospective study in northern Japan.

Treatment and prognosis of subglottic cancers: a 10-year, multicenter, retrospective study in northern Japan.

Journal: Oral oncology

Published: December 26, 2025

Cisplatin-induced genetic alterations in KEAP1 promote therapeutic resistance in head and neck squamous cell carcinoma.

Cisplatin-induced genetic alterations in KEAP1 promote therapeutic resistance in head and neck squamous cell carcinoma.

Journal: Redox biology

Published: August 04, 2025

Treatment outcomes of definitive radiotherapy for unresectable salivary gland cancers: a multicenter, retrospective study in northern Japan.

Treatment outcomes of definitive radiotherapy for unresectable salivary gland cancers: a multicenter, retrospective study in northern Japan.

Journal: Japanese journal of clinical oncology

Published: July 02, 2025

Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study.

Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study.

Journal: Cancer

Published: June 19, 2025

Showing 1-12 of 64

Last Updated: 09/26/2026